Sánchez-Vicente JL, Muñoz-Morales A, Galván-Carrasco MP, Castilla-Lázpita A, Vital-Berral C, Alfaro-Juárez A, Rueda-Rueda T. Radiation maculopathy treated with intravitreal bevacizumab.
ACTA ACUST UNITED AC 2016;
92:283-286. [PMID:
27894518 DOI:
10.1016/j.oftal.2016.10.008]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2016] [Revised: 09/26/2016] [Accepted: 10/03/2016] [Indexed: 11/15/2022]
Abstract
CASE REPORT
A 47 year-old woman with a choroidal melanoma developed a macular oedema secondary to radiation therapy 75 months after brachytherapy plaque. The patient received 3 intravitreal Bevacizumab injections.
DISCUSSION
The patient had a good response to bevacizumab treatment. In fact, there was a reduction in the macular oedema measured by optical coherence tomography (OCT) scan, as well as an improvement in best corrected visual acuity. There was no recurrence of macular oedema, and visual acuity remained stable after 3-years follow-up.
Collapse